Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces it has now recruited the first three patients for its Phase IIa trial of its molecule QGC001.
This first-in-class drug candidate of the new class of therapeutics for the treatment of high blood pressure, in November 2014 obtained the authorisations from ANSM (the French national drug and health products safety agency) and CPP (the French consumer protection agency) to start Phase IIa trials aimed at proving its effectiveness in hypertensive patients.
[button link=”http://www.quantum-genomics.com/www/wp-content/uploads/2015/03/QGC_CP_Recrutement-1ers-patients_03032015_VF_EN.pdf” target=”_blank” title=”Download press release” size=”small” color=”red”]